The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego
Tecentriq SC reduces treatment administration time by nearly 80 percent and has the potential to lower indirect treatment costs
30,000 sq. ft. multispeciality facility aims to deliver integrated care for women across every life stage
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
